Open access · US-GOV
via ClinicalTrials.gov Clinical trial
HMB for Denutrition in Patients With Cirrhosis (HEPATIC)
Authors not listed
Instituto Aragones de Ciencias de la Salud · 2017
Abstract
Cirrhosis is a late stage of hepatic fibrosis caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcoholism. The World Health Organization (WHO) has reported that this condition accounts for 1.8% of all deaths in Europe (170,000 deaths/year).
Patients with cirrhosis are characterized by severe metabolic alterations, which converge in a malnutritional state. Malnutrition encompasses glucose intolerance, chronic inflammation, altered gut microbiota, reduced muscle mass (sarcopenia), as well as loss and dysregulation of adipose tissue (adipopenia). Malnutrition is the most frequent complication that adversely affects the outcomes of cirrhotic patients. Yet, despite its clinical repercussions and potential reversibility, there are no effective therapies because our limited understanding of the mechanisms underlying this altered metabolism.
β-hydroxy β-methylbutyrate (HMB) is a naturally produced substance regarded as safe and effective in preventing muscle loss during chronic diseases. Previous studies have indicated some beneficial effects of HMB itself or its parent metabolite, leucine, on adipose tissue, glucose intolerance, inflammation, and gut microbiota. This study aims to translate those beneficial effects to cirrhotic patients. The investigators hypothesize that HMB can improve cirrhosis-related metabolic abnormalities through its pleiotropic effects. The goals of this study are: i) to perform a randomized clinical trial to evaluate the efficacy of HMB, administered as nutritional supplementation, on clinical symptoms of cirrhosis.
ii) to uncover the precise metabolic pathways that underlie HMB action, with a special focus on muscle, adipose tissue, and gut microbiota.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-18 MST
Cite this
APA
Anonymous. (2017). HMB for Denutrition in Patients With Cirrhosis (HEPATIC). <em>Instituto Aragones de Ciencias de la Salud</em>. https://clinicaltrials.gov/study/NCT03285217
Vancouver
Anonymous. HMB for Denutrition in Patients With Cirrhosis (HEPATIC). Instituto Aragones de Ciencias de la Salud. 2017.
BibTeX
@misc{anon2017HMBfor,
title = {HMB for Denutrition in Patients With Cirrhosis (HEPATIC)},
author = {Anonymous},
journal = {Instituto Aragones de Ciencias de la Salud},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Affiliated Hospital of Qingdao University 2021
Open access · US-GOV
Affiliated Hospital of Qingdao University
Chang Gung Memorial Hospital 2022
Open access · US-GOV
Study the Impact of Hirsutella Sinensis Nutrient Supplements Has on Improving Muscle Health and Metabolism in Elderly
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 2023
Open access · US-GOV
Prospective Study of Ultrasound Assessment of Sarcopenia and Correlated Clinical Outcomes in Patients With Chronic Liver Disease: the SARCOLIVER Study
Frontiers in Immunology 2017
Open access · CC-BY
Aging, Obesity, and Inflammatory Age-Related Diseases
University of Roma La Sapienza 2019
Open access · US-GOV
Beta-Hydroxy-Beta-Methylbutyrate Supplementation and Physical Activity in Liver Cirrhosis: a Controlled Trial
Antioxidants 2021
Open access · CC-BY